Moderna, Inc. (MRNA) stock
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)
Close on Nov 17, 2026Market cap $82.56BP/E –Yield –
Moderna pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Moderna's pe ratio was 28.1× on Oct 31, 2023, against 4.6× a year earlier. Over the last 3 years it ranged from 3.6× to 282.9×, with a median of 10.2×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Oct 31, 2023 | 28.1× | +21.6 |
| 2022 | Dec 30, 2022 | 6.5× | −9.1 |
| 2021 | Dec 31, 2021 | 15.6× | – |
See a number that looks wrong?